Bukwang Pharm to commercialize hepatitis B drug clevudine in 2004
Published: 2002-12-04 06:56:00
Updated: 2002-12-04 06:56:00
Bukwang Pharm said it would commercialize an innovative hepatitis B drug, clevudine (L-Fmau-102), nucleoside analogue, in 2004, as the phase IIb clinical trials in eight university hospital in Korea, demonstrated its excellent antiviral activity.
Clevudine has proven to manifest its sustained ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
